The DOI matches its Crossref record; 784 of the 784 references it cites were found in a registry or an index.
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Open accessAbstract
Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45+ cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–600 of 784
Zhang, D., Li, A. M., Hu, G., Huang, M., Yang, F., Zhang, L., Wellen, K. E., Xu, X., Conn, C. S., Zou, W., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.010 · Cited by 151
Self-citationKim, S. H., Li, M., Trousil, S., Zhang, Y., di Magliano, M. P., Swanson, K. D., & Zheng, B. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.033 · Cited by 150
Yin, J., Kim, S. S., Choi, E., Oh, Y. T., Lin, W., Kim, T. H., Sa, J. K., Hong, J. H., Park, S., Kwon, H. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16789-2 · Cited by 150
Nicotinamide metabolism regulates glioblastoma stem cell maintenance
Jung, J., Kim, L. J. Y., Wang, X., Wu, Q., Sanvoranart, T., Hubert, C. G., Prager, B. C., Wallace, L. C., Jin, X., Mack, S. C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.90019 · Cited by 149
Context-Dependent Glioblastoma–Macrophage/Microglia Symbiosis and Associated Mechanisms
Xuan, W., Lesniak, M. S., James, C. D., Heimberger, A. B., & Chen, P. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.004 · Cited by 149
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
Therapeutic targeting of c-KIT in cancer
Ashman, L. K., & Griffith, R. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.740010 · Cited by 147
Blocking IDO activity to enhance anti-tumor immunity
Munn, D. H. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e414 · Cited by 146
Zheng, Z., Zhang, J., Jiang, J., He, Y., Zhang, W., Mo, X., Kang, X., Xu, Q., Wang, B., & Huang, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000207 · Cited by 144
Ma, W., Wang, Y., Zhang, R., Yang, F., Zhang, D., Huang, M., Zhang, L., Dorsey, J. F., Binder, Z. A., O’Rourke, D. M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00147-8 · Cited by 143
Role of hyaluronan in glioma invasion
Park, J. B., Kwak, H., & Lee, S. (2008) · Cell Adhesion & Migration · doi:10.4161/cam.2.3.6320 · Cited by 142
Wu, A., Maxwell, R., Xia, Y., Cardarelli, P. M., Oyasu, M., Belcaid, Z., Kim, E. S., Hung, A. L., Luksik, A. S., Garzón-Muvdi, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03172-5 · Cited by 142
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs
Porta, C., Consonni, F. M., Morlacchi, S., Sangaletti, S., Bleve, A., Totaro, M. G., Larghi, P., Rimoldi, M., Tripodo, C., Strauss, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2843 · Cited by 142
Zhai, L., Bell, A., Ladomersky, E., Lauing, K. L., Bollu, L., Nguyen, B., Genet, M., Kim, M., Chen, P., Mi, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1392 · Cited by 142
Endothelium-Microenvironment Interactions in the Developing Embryo and in the Adult
Red‐Horse, K., Crawford, Y., Shojaei, F., & Ferrara, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.013 · Cited by 141
Hu, J., Zhao, Q., Kong, L.-Y., Wang, J., Yan, J., Xia, X., Jia, Z., Heimberger, A. B., & Li, S. (2021) · Science Advances · doi:10.1126/sciadv.abc2511 · Cited by 141
Inamoto, S., Itatani, Y., Yamamoto, T. S., Minamiguchi, S., Hirai, H., Iwamoto, M., Hasegawa, S., Taketo, M. M., Sakai, Y., & Kawada, K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0726 · Cited by 140
Vogelbaum, M. A., Sampson, J. H., Kunwar, S., Chang, S. M., Shaffrey, M. E., Asher, A. L., Lang, F. F., Croteau, D. J., Parker, K., Grahn, A. Y., et al. (2007) · Neurosurgery · doi:10.1227/01.neu.0000303199.77370.9e · Cited by 139
Silver, D. J., Siebzehnrübl, F. A., Schildts, M. J., Yachnis, A. T., Smith, G. M., Smith, A., Scheffler, B., Reynolds, B. A., Silver, J., & Steindler, D. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3004-12.2013 · Cited by 139
Qiu, W., Guo, X., Li, B., Wang, J., Qi, Y., Chen, Z., Zhao, R., Deng, L., Qian, M., Wang, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.023 · Cited by 139
In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory site
Haverkamp, J. M., Crist, S. A., Elzey, B. D., Bozkus, C. C., & Ratliff, T. L. (2011) · European Journal of Immunology · doi:10.1002/eji.201041069 · Cited by 138
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy
Wang, Y., Johnson, K. C. C., Gatti-Mays, M. E., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01335-y · Cited by 138
Sun, R., Luo, H., Su, J., Di, S., Zhou, M., Shi, B., Sun, Y., Du, G., Zhang, H., Jiang, H., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.034 · Cited by 137
Wang, M., Cai, Y., Peng, Y., Xu, B., Hui, W., & Jiang, Y. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03042-3 · Cited by 136
Chen, X., Ma, H., Wang, Z., Zhang, S., Yang, H., & Fang, Z. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1139 · Cited by 135
Self-citationImpaired capacity for upregulation of MHC class II in tumor‐associated microglia
Schartner, J. M., Hagar, A. R., Handel, M. M. V., Zhang, L., Nadkarni, N. V., & Badie, B. (2005) · Glia · doi:10.1002/glia.20201 · Cited by 134
Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma
Chen, A., Jiang, Y., Li, Z., Wu, L., Santiago, U., Zou, H., Cai, C., Sharma, V., Guan, Y., McCarl, L. H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147552 · Cited by 134
Immunocytokines are a promising immunotherapeutic approach against glioblastoma
Weiss, T., Puca, E., Silginer, M., Hemmerle, T., Pazahr, S., Bink, A., Weller, M., Neri, D., & Roth, P. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2311 · Cited by 133
Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma
Lee, J., Nicosia, M., Hong, E. S., Silver, D. J., Li, C., Bayık, D., Watson, D. C., Lauko, A. J., Kay, K. E., Wang, S. Z., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0869 · Cited by 133
CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice
Haile, L. A., Gamrekelashvili, J., Manns, M. P., Korangy, F., & Greten, T. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903573 · Cited by 132
Reardon, D. A., Groves, M. D., Wen, P. Y., Nabors, B., Mikkelsen, T., Rosenfeld, S., Raizer, J. J., Barriuso, J., McLendon, R. E., Suttle, A. B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1707 · Cited by 132
Disconnecting multicellular networks in brain tumours
Venkataramani, V., Schneider, M. B., Giordano, F. A., Kuner, T., Wick, W., Herrlinger, U., & Winkler, F. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00475-0 · Cited by 132
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
Su, Y., Banerjee, S., White, S. V., & Kortylewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061803 · Cited by 131
Blood-brain barrier, cytotoxic chemotherapies and glioblastoma
Dréan, A., Goldwirt, L., Verreault, M., Canney, M. S., Schmitt, C., Guehennec, J., Delattre, J., Carpentier, A. C., & Idbaïh, A. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1202761 · Cited by 130
CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone
Goffart, N., Lombard, A., Lallemand, F., Kroonen, J., Nassen, J., Valentin, E. D., Berendsen, S., Dedobbeleer, M., Willems, E., Robe, P. A. J. T., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now136 · Cited by 130
Alicea-Torres, K. M., Sanseviero, E., Gui, J., Chen, J., Veglia, F., Yu, Q., Donthireddy, L., Kossenkov, A. V., Lin, C., Fu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22033-2 · Cited by 130
Geraldo, L. H., Xu, Y., Jacob, L., Pibouin-Fragner, L., Rao, R., Maïssa, N., Verreault, M., Lemaire, N., Knosp, C. A., Lesaffre, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141083 · Cited by 130
Chromatin Regulator PRC2 Is a Key Regulator of Epigenetic Plasticity in Glioblastoma
Natsume, A., Ito, M., Katsushima, K., Ohka, F., Hatanaka, A., Shinjo, K., Sato, S., Takahashi, S., Ishikawa, Y., Takeuchi, I., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0109 · Cited by 129
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Guha, P., Gardell, J., Darpolor, J. K., Cunetta, M., Lima, M., Miller, G., Espat, N. J., Junghans, R. P., & Katz, S. C. (2018) · Oncogene · doi:10.1038/s41388-018-0449-z · Cited by 128
E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression
Yang, R., Wang, M., Zhang, G., Bao, Y., Wu, Y., Li, X., Yang, W., & Cui, H. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01032-y · Cited by 128
Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma
Torrini, C., Nguyen, T. T. T., Shu, C., Mela, A., Humala, N., Mahajan, A., Seeley, E., Zhang, G., Westhoff, M., Karpel‐Massler, G., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.06.030 · Cited by 128
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 127
The Mechanisms of Action of Tumor Treating Fields
Moser, J. C., Salvador, E., Deniz, K., Swanson, K. D., Tuszyński, J. A., Carlson, K. W., Karanam, N. K., Patel, C. B., Story, M. D., Lou, E., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0887 · Cited by 127
Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer
Metelli, A., Salem, M. A., Wallace, C. H., Wu, B. X., Li, A., Li, X., & Li, Z. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0570-z · Cited by 126
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 126
Circadian regulation of cancer cell and tumor microenvironment crosstalk
Xuan, W., Khan, F., James, C. D., Heimberger, A. B., Lesniak, M. S., & Chen, P. (2021) · Trends in Cell Biology · doi:10.1016/j.tcb.2021.06.008 · Cited by 126
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma
Xuan, W., Hsu, W.-H., Khan, F., Dunterman, M., Pang, L., Wainwright, D. A., Ahmed, A. U., Heimberger, A. B., Lesniak, M. S., & Chen, P. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0559 · Cited by 126
Tejero, R., Huang, Y., Katsyv, I., Kluge, M., Lin, J., Tomé-García, J., Daviaud, N., Wang, Y., Zhang, B., Tsankova, N. M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.064 · Cited by 125
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma
Wang, Z., Hu, P., Tang, F., Lian, H., Chen, X., Zhang, Y., He, X., Liu, W., & Xie, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.001 · Cited by 123
Sen, T., Corte, C. M. D., Milutinovic, S., Cardnell, R. J., Diao, L., Ramkumar, K., Gay, C. M., Stewart, C. A., Fan, Y.-H., Shen, L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.009 · Cited by 123
Targeting A2 adenosine receptors in cancer
Allard, D., Turcotte, M., & Stagg, J. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.8 · Cited by 122
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yan, J., Zhao, Q., Gabrusiewicz, K. R., Kong, L.-Y., Xia, X., Wang, J., Ott, M., Xu, J., Davis, R. E., Huo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08271-x · Cited by 122
Rao, G., Latha, K., Ott, M., Sabbagh, A., Marisetty, A., Ling, X., Zamler, D. B., Doucette, T. A., Yang, Y., Kong, L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4110 · Cited by 122
Dewdney, B., Jenkins, M. R., Best, S. A., Freytag, S., Prasad, K., Holst, J., Endersby, R., & Johns, T. G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01637-8 · Cited by 122
Kozielski, K., Ruiz‐Valls, A., Tzeng, S. Y., Guerrero‐Cazares, H., Rui, Y., Li, Y., Vaughan, H. J., Gionet‐Gonzales, M., Vantucci, C. E., Kim, J., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.020 · Cited by 121
c-Rel is a myeloid checkpoint for cancer immunotherapy
Li, T., Li, X., Zamani, A., Wang, W., Lee, C., Li, M., Luo, G., Eiler, E., Sun, H., Ghosh, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0061-3 · Cited by 120
Lan, J., Li, R., Yin, L., Deng, L., Gui, J., Chen, B.-Q., Zhou, L., Meng, M., Huang, Q., Mo, X., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.01.071 · Cited by 119
CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma
Lupo, K. B., & Matosevic, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00913-2 · Cited by 118
Guo, Q., Dai, X., Yin, M., Cheng, H., Qian, H., Wang, H., Zhu, D., & Wang, X. (2022) · Military Medical Research · doi:10.1186/s40779-022-00386-z · Cited by 118
Ausejo‐Mauleon, I., Labiano, S., de la Nava, D., Laspidea, V., Zalacaín, M., Marrodán, L., García-Moure, M., González-Huarriz, M., Hervás-Corpión, I., Dhandapani, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.001 · Cited by 118
Gielen, P. R., Schulte, B. M., Kers‐Rebel, E. D., Verrijp, K. C. N., Petersen-Baltussen, H. M. J. M., ter Laan, M., Wesseling, P., & Adema, G. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000183 · Cited by 117
The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression
Wu, W., Yu, T., Wu, Y., Tian, W., Zhang, J., & Wang, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1132-0 · Cited by 117
Peereboom, D. M., Alban, T. J., Grabowski, M. M., Alvarado, A. G., Otvos, B., Bayık, D., Roversi, G. A., McGraw, M., Huang, P., Mohammadi, A. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130748 · Cited by 117
CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future
Lin, Y.-J., Mashouf, L. A., & Lim, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817296 · Cited by 117
Blocking IDO activity to enhance anti-tumor immunity
David, H. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/414 · Cited by 116
Chen, Q., Han, B. R., Meng, X., Duan, C., Yang, C., Wu, Z., Dinislam, M., Zhao, S., Safin, S. M., Jiang, C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32102 · Cited by 116
Epigenomic Reprogramming as a Driver of Malignant Glioma
Phillips, R. E., Soshnev, A. A., & Allis, C. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.008 · Cited by 116
Mouse models of neutropenia reveal progenitor-stage-specific defects
Muench, D. E., Olsson, A., Ferchen, K., Pham, G., Serafin, R. A., Chutipongtanate, S., Dwivedi, P., Song, B., Hay, S., Chetal, K., et al. (2020) · Nature · doi:10.1038/s41586-020-2227-7 · Cited by 115
Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors
Tocut, M., Brenner, R. M., & Zandman‐Goddard, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.010 · Cited by 115
Bauer, R., Udonta, F., Wroblewski, M., Batalla, I. B., Santos, I. M., Taverna, F., Kuhlencord, M., Gensch, V., Päsler, S., Vinckier, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3415 · Cited by 115
Mastio, J., Condamine, T., Dominguez, G., Kossenkov, A. V., Donthireddy, L., Veglia, F., Lin, C., Wang, F., Fu, S., Zhou, J., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181952 · Cited by 115
Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias
Hu, C., Leche, C. A., Kiyatkin, A. B., Yu, Z., Stayrook, S. E., Ferguson, K. M., & Lemmon, M. A. (2022) · Nature · doi:10.1038/s41586-021-04393-3 · Cited by 115
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., Guehennec, J., Knoff, D., Labussière, M., Marie, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1015 · Cited by 114
Tacchio, M. D., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 113
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 113
Yin, Y., Rodriguez, J. L., Li, N., Thokala, R., Nasrallah, M. P., Hu, L., Zhang, L., Zhang, J. V., Logun, M. T., Kainth, D., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.011 · Cited by 111
Neuronal and tumourigenic boundaries of glioblastoma plasticity
Silva, M. I. D., Stringer, B. W., & Bardy, C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.010 · Cited by 111
Hamblett, K. J., Kozlosky, C. J., Siu, S., Chang, W., Liu, H., Foltz, I. N., Trueblood, E. S., Meininger, D. P., Arora, T., Twomey, B., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-1078 · Cited by 110
McClure, C., Brudecki, L. E., Ferguson, D. A., Yao, Z. Q., Moorman, J. P., McCall, C. E., & Gazzar, M. E. (2014) · Infection and Immunity · doi:10.1128/iai.01495-14 · Cited by 110
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Kiyokawa, J., Kawamura, Y., Ghouse, S. M., Acar, S., Barçın, E., Martínez‐Quintanilla, J., Martuza, R. L., Alemany, R., Rabkin, S. D., Shah, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2400 · Cited by 110
Sa, J. K., Chang, N., Lee, H. W., Cho, H. J., Ceccarelli, M., Cerulo, L., Yin, J., Kim, S. S., Caruso, F. P., Lee, M., et al. (2020) · Genome biology · doi:10.1186/s13059-020-02140-x · Cited by 109
Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes
Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 108
Waight, J. D., Chand, D. S., Dietrich, S., Gombos, R. B., Horn, T. L., Gonzalez, A. M., Manrique, M. L., Swiech, L. J., Morin, B. M., Brittsan, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.005 · Cited by 108
Xiong, A., Zhang, J., Chen, Y., Zhang, Y., & Yang, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104239 · Cited by 108
Chen, H.-M., Ma, G., Gildener‐Leapman, N., Eisenstein, S. G., Coakley, B. A., Ozao, J. J., Mandeli, J., Divino, C. M., Schwartz, M., Sung, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2742 · Cited by 106
Microenvironmental Heterogeneity in Brain Malignancies
Perus, L. J. M., & Walsh, L. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02294 · Cited by 106
Chen, Z., Ross, J., & Hambardzumyan, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902366116 · Cited by 105
Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A. V., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0986 · Cited by 104
Yan, J., Kong, L.-Y., Hu, J., Gabrusiewicz, K. R., Dibra, D., Xia, X., Heimberger, A. B., & Li, S. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv137 · Cited by 103
Iwata, T., Kondo, Y., Kimura, O. S., Morosawa, T., Fujisaka, Y., Umetsu, T., Kogure, T., Inoue, J., Nakagome, Y., & Shimosegawa, T. (2016) · Scientific Reports · doi:10.1038/srep39296 · Cited by 103
Huang, N., Li, F., Zhang, M., Zhou, H., Chen, Z., Ma, X., Yang, L., Wu, X., Zhong, J., Xiao, F., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.12.008 · Cited by 102
Glioblastoma Therapy in the Age of Molecular Medicine
Geraldo, L. H., Garcia, C., da Fonseca, A. C. C., Dubois, L. G., Spohr, T. C. L. D. S. E., Matias, D., Magalhães, E. S. D. C., do Amaral, R. F., da Rosa, B. G., Grimaldi, I., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.002 · Cited by 101
Okła, K., Czerwonka, A., Wawruszak, A., Bobiński, M. S., Bilska, M., Tarkowski, R., Bednarek, W., Wertel, I., & Kotarski, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00691 · Cited by 101
Newman, J. P. A., Wang, G., Arima, K., Guan, S. P., Waters, M. R., Cavenee, W. K., Pan, E., Aliwarga, E., Chong, S. T., Kok, C. Y. L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01392-9 · Cited by 100
CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains
Shiina, S., Ohno, M., Ohka, F., Kuramitsu, S., Yamamichi, A., Kato, A., Motomura, K., Tanahashi, K., Yamamoto, T., Watanabe, R., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0060 · Cited by 99
Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity
Bourgeois‐Daigneault, M., Roy, D. G., Falls, T. J., Twumasi‐Boateng, K., St-Germain, L. E., Marguerie, M., Garcia, V., Selman, M., Jennings, V. A., Pettigrew, J. L., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.1 · Cited by 99
An overview of MCT1 and MCT4 in GBM: small molecule transporters with large implications.
Park, S. J., Smith, C. P., Wilbur, R. R., Cain, C. P., Kallu, S. R., Valasapalli, S., Sahoo, A., Guda, M. R., Tsung, A. J., & Velpula, K. K. (2018) · Europe PMC (PubMed Central) · Cited by 99
Generation of Myeloid Cells in Cancer: The Spleen Matters
Wu, C., Hua, Q., & Zheng, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01126 · Cited by 99
BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network
Sun, X. S., Klingbeil, O., Lu, B., Wu, C., Ballon, C., Ouyang, M., Wu, X., Jin, Y., Hwangbo, Y., Huang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05551-x · Cited by 99
Li, L., Li, Z., Meng, X., Wang, X., Song, D., Liu, Y., Xu, T., Qin, J., Sun, N., Tian, K., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216467 · Cited by 98
Hassel, J. C., Jiang, H., Bender, C., Winkler, J. K., Sevko, A., Shevchenko, I., Halama, N., Dimitrakopoulou‐Strauss, A., Haefeli, W. E., Jäger, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326440 · Cited by 97
Bitsch, R., Kurzay, A., Kurt, F. G. Ö., Torre, C. D. L., Lasser, S., Lepper, A., Siebenmorgen, A., Müller, V. A., Altevogt, P., Utikal, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004384 · Cited by 97
Ζαννίκου, Μ., Duffy, J. T., Levine, R., Seblani, M. D., Liu, Q., Presser, A., Arrieta, V. A., Chen, C. J., Sonabend, A. M., Horbinski, C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006239 · Cited by 97
Izaguirre, D. I., Zhu, W., Hai, T., Beird, H. C., Krahe, R., & Cote, G. J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20859 · Cited by 96
Trellakis, S., Bruderek, K., Hütte, J., Elian, M., Hoffmann, T. K., Lang, S., & Brandau, S. (2012) · Innate Immunity · doi:10.1177/1753425912463618 · Cited by 96
EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment
Yin, Y., Qiu, S., Li, X., Huang, B., Xu, Y., & Peng, Y. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0993-4 · Cited by 96
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 96
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Shastri, A., Choudhary, G. S., Teixeira, M., Gordon-Mitchell, S., Ramachandra, N., Bernard, L., Bhattacharyya, S., Lopez, R., Pradhan, K., Giricz, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120156 · Cited by 96
Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M. T. S., Tang, W., Feng, Y., Xu, L., Chan, A. W. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07402-8 · Cited by 95
Tian, L., Xu, B., Chen, Y., Li, Z., Wang, J., Zhang, J., Ma, R., Cao, S., Hu, W., Chiocca, E. A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00448-0 · Cited by 95
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., Granda‐Díaz, R., Martínez‐Pérez, A., Aguilar-García, C., Rodrigo, J. P., Garcia-Pedrero, J. M., & Gonzalez, S. R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01845-4 · Cited by 95
Daniele, S., Giacomelli, C., Zappelli, E., Granchi, C., Trincavelli, M. L., Minutolo, F., & Martini, C. (2015) · Scientific Reports · doi:10.1038/srep15556 · Cited by 94
Pituch, K. C., Miska, J. M., Krenciute, G., Panek, W. K., Li, G., Rodríguez-Cruz, T., Wu, M., Han, Y., Lesniak, M. S., Gottschalk, S. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.001 · Cited by 94
Alghamri, M. S., McClellan, B. L., Avvari, R., Thalla, R., Carney, S. V., Hartlage, C. S., Haase, S., Ventosa, M., Taher, A. W., Kamran, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh3243 · Cited by 94
Kim, E. H., Kim, Y. J., Song, H. S., Jeong, Y. K., Lee, J. Y., Sung, J., Yoo, S., & Yoon, M. (2016) · Oncotarget · doi:10.18632/oncotarget.11407 · Cited by 93
Himes, B. T., Peterson, T. E., de Mooij, T., Garcia, L. M. C., Jung, M.-Y., Uhm, S. A., Yan, D. Z., Tyson, J., Jin‐Lee, H. J., Parney, D., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa029 · Cited by 93
Marin, B. M., Porath, K. A., Jain, S., Kim, M., Conage‐Pough, J. E., Oh, J., Miller, C. L., Talele, S., Kitange, G. J., Tian, S., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab133 · Cited by 93
Qiu, Z., Zhao, L., Shen, J., Liang, Z., Wu, Q., Yang, K., Min, L., Gimple, R. C., Yang, Q., Bhargava, S., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1848 · Cited by 93
Zhong, J., Yang, X., Chen, J., He, K., Gao, X., Wu, X., Zhang, M., Zhou, H., Xiao, F., An, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32311-2 · Cited by 93
Zhang, H., Zhang, N., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, Z., Zhang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac386 · Cited by 93
Haase, S., Banerjee, K., Mujeeb, A., Hartlage, C. S., Núñez, F. M., Núñez, F. J., Alghamri, M. S., Kadiyala, P., Carney, S. V., Barissi, M. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154229 · Cited by 93
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer
Sigmond, J., Honeywell, R. J., Postma, T. J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn543 · Cited by 92
Huang, X., Dubuc, A. M., Hashizume, R., Berg, J., He, Y., Wang, J., Chiang, C. C., Cooper, M. K., Northcott, P. A., Taylor, M. D., et al. (2012) · Genes & Development · doi:10.1101/gad.193789.112 · Cited by 92
Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 92
Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma
Liu, S., Zhang, C., Maimela, N. R., Li, Y., Zhang, Z., Yü, P., Huang, L. J., & Zhang, Y. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601478 · Cited by 92
Active CREB1 Promotes a Malignant TGFβ2 Autocrine Loop in Glioblastoma
Rodón, L., Gonzàlez-Juncà, A., Inda, M. D. M., Sala-Hojman, A., Martínez-Sáez, E. A., & Seoane, J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0275 · Cited by 90
P-selectin axis plays a key role in microglia immunophenotype and glioblastoma progression
Yeini, E., Ofek, P., Pozzi, S., Albeck, N., Ben‐Shushan, D., Tiram, G., Golan, S., Kleiner, R., Sheinin, R., Dangoor, S. I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22186-0 · Cited by 90
Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity
Verschuere, T., Toelen, J., Maes, W., Poirier, F., Boon, L., Tousseyn, T., Mathivet, T., Gerhardt, H., Mathieu, V., Robert Kiss, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28426 · Cited by 88
GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway
Yu, S., Yu, X., Sun, L., Zheng, Y., Chen, L., Xu, H., Jin, J., Lan, Q., Chen, C. C., & Li, M. (2020) · Oncogene · doi:10.1038/s41388-020-1348-7 · Cited by 88
Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome
Pimenta, M. G., Otero, Á., Guzmán, D. Á. A., Argente, D. P., Martín, L. R., Sousa-Casasnovas, P., García-Martín, A., de Oca, J. C. R. M., Ledezma, J. J. V., Carretero, L. T., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12927 · Cited by 88
Yi, L., Cui, Y., Xu, Q., & Jiang, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.5099 · Cited by 87
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.12.002 · Cited by 87
Smith, A. D., Lu, C., Payne, D., Paschall, A. V., Klement, J. D., Redd, P. S., Ibrahim, M. L., Yang, D., Han, Q., Liu, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3670 · Cited by 87
Reactive oxygen species in immune cells: A new antitumor target
Wang, L., Kuang, Z., Zhang, D., Gao, Y., Ying, M., & Wang, T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110978 · Cited by 87
Self-citationPrice, G. A., Bouras, A., Hambardzumyan, D., & Hadjipanayis, C. G. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103453 · Cited by 87
Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
Zhang, H., Song, Y., Yang, H., Liu, Z., Gao, L., Liang, X., & Ma, C. (2018) · Oncogene · doi:10.1038/s41388-018-0140-4 · Cited by 86
Self-citationRaphael, I., Kumar, R., McCarl, L. H., Shoger, K. E., Wang, L., Sandlesh, P., Sneiderman, C. T., Allen, J., Zhai, S., Campagna, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637146 · Cited by 86
Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma
Pang, L., Dunterman, M., Xuan, W., Gonzalez, A. M., Lin, Y., Hsu, W.-H., Khan, F., Hagan, R. S., Müller, W. A., Heimberger, A. B., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112127 · Cited by 86
Shahar, T., Rozovski, U., Hess, K. R., Hossain, A., Gumin, J., Gao, F., Fuller, G. N., Goodman, L. D., Sulman, E. P., & Lang, F. F. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now239 · Cited by 85
Xu, M., Zhao, Z., Song, J., Lan, X., Lu, S., Chen, M., Wang, Z., Chen, W., Fan, X., Wu, F., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.01.008 · Cited by 85
Longhitano, L., Vicario, N., Forte, S., Giallongo, C., Broggi, G., Caltabiano, R., Barbagallo, G. M. V., Altieri, R., Raciti, G., Rosa, M. D., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03215-3 · Cited by 85
Kreatsoulas, D. C., Bolyard, C. M., Wu, B. X., Çam, H., Giglio, P., & Li, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01298-0 · Cited by 85
Gu, M., Jiang, H., Tan, M., Yu, L., Xu, N., Li, Y., Wu, H., Hou, Q., & Dai, C. (2023) · Nature Communications · doi:10.1038/s41467-023-42476-z · Cited by 85
Netherby, C. S., Messmer, M. N., Burkard-Mandel, L. E., Colligan, S. H., Miller, A., Gomez, E. C., Wang, J., Nemeth, M. J., & Abrams, S. I. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601722 · Cited by 83
Dorneburg, C., Fischer, M., Barth, T. F. E., Mueller‐Klieser, W., Hero, B., Gecht, J., Carter, D. R., Preter, K. D., Mayer, B., Christner, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2578 · Cited by 83
Takacs, G. P., Kreiger, C. J., Luo, D., Tian, G., Garcia, J. S., Deleyrolle, L. P., Mitchell, D. A., & Harrison, J. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993444 · Cited by 83
Lee, M., Park, C., Lee, Y.-R., Im, S., Song, S., & Lee, C. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0379-4 · Cited by 82
Dávila‐González, D., Choi, D. S., Rosato, R. R., Granados-Principal, S. M., Kuhn, J. G., Li, W., Qian, W. P., Chen, W., Kozielski, A. J., Wong, H. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1437 · Cited by 82
Neutrophils as myeloid‐derived suppressor cells
Aarts, C. E. M., & Kuijpers, T. W. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12989 · Cited by 82
Reichel, C. A., Puhr‐Westerheide, D., Zuchtriegel, G., Uhl, B., Berberich, N., Zahler, S., Wymann, M. P., Luckow, B., & Krombach, F. (2012) · Blood · doi:10.1182/blood-2012-01-402164 · Cited by 81
CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D
Bruns, H., Böttcher, M., Qorraj, M., Fabri, M., Jitschin, S., Dindorf, J., Busch, L., Jitschin, R., Mackensen, A., & Mougiakakos, D. (2016) · Leukemia · doi:10.1038/leu.2016.378 · Cited by 81
Wang, Z., Su, G.-H., Dai, Z., Meng, M., Zhang, H., Fan, F., Liu, Z., Zhang, L., Weygant, N., He, F., et al. (2021) · Cell Proliferation · doi:10.1111/cpr.12988 · Cited by 81
Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells
Kim, E. H., Jo, Y., Sai, S., Park, M.-J., Kim, J., Kim, J. S., Lee, Y., Cho, J.-M., Kwak, S., Baek, J.-H., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0882-7 · Cited by 80
Tcyganov, E. N., Hanabuchi, S., Hashimoto, A., Campbell, D. G., Kar, G., Slidel, T. W. F., Cayatte, C., Landry, A. L., Pilataxi, F., Hayes, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145971 · Cited by 80
Rodero, M. P., Marie, Y., Coudert, M., Blondet, E., Mokhtari, K., Rousseau, A., Raoul, W., Carpentier, C., Sennlaub, F., Déterre, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2833 · Cited by 79
Wang, M., Jia, J., Cui, Y., Peng, Y., & Jiang, Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04359-3 · Cited by 79
Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma
Pang, L., Guo, S., Khan, F., Dunterman, M., Ali, H. A., Liu, Y., Huang, Y.-Y., & Chen, P. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101238 · Cited by 79
Ostrand‐Rosenberg, S., Horn, L. A., & Ciavattone, N. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00215 · Cited by 77
Antibody–drug conjugates: an emerging modality for the treatment of cancer
Leal, M., Sapra, P., Hurvitz, S. A., Senter, P. D., Wahl, A. F., Schutten, M. M., Shah, D. K., Haddish‐Berhane, N., & Kabbarah, O. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12499 · Cited by 76
Gai, Q., Fu, Z., He, J., Mao, M., Yao, X., Qin, Y., Lan, X., Zhang, L., Miao, J., Wang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00855-2 · Cited by 76
VEGF as a modulator of the innate immune response in glioblastoma
Turkowski, K., Brandenburg, S., Mueller, A., Kremenetskaia, I., Bungert, A. D., Blank, A., Felsenstein, M., & Vajkoczy, P. (2017) · Glia · doi:10.1002/glia.23234 · Cited by 75
Pilanc, P., Wojnicki, K., Roura, A.-J., Cyranowski, S., Ellert‐Miklaszewska, A., Ochocka, N., Gielniewski, B., Grzybowski, M. M., Błaszczyk, R., Stańczak, P. S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703465 · Cited by 75
Hammami, I., Chen, J., Murschel, F., Bronte, V., Crescenzo, G. D., & Jolicœur, M. (2012) · BMC Cell Biology · doi:10.1186/1471-2121-13-18 · Cited by 74
TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
Li, S., Sun, R., Chen, Y., Wei, H., & Tian, Z. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2371 · Cited by 74
Mittal, S., Klinger, N. V., Michelhaugh, S. K., Barger, G. R., Pannullo, S. C., & Juhász, C. (2017) · Journal of neurosurgery · doi:10.3171/2016.9.jns16452 · Cited by 74
Garcia-Diaz, C., Pöysti, A., Mereu, E., Clements, M., Brooks, L. J., Gálvez‐Cancino, F., Castillo, S. P., Tang, W., Beattie, G., Courtot, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112472 · Cited by 74
Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma
Martino, M. D., Daviaud, C., Minns, H. E., Lazarian, A., Wacker, A. S., Costa, A. P. F., Attarwala, N., Chen, Q., Choi, S., Rabadán, R., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216329 · Cited by 74
LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression
Chai, E., Zhang, L., & Li, C. (2019) · Cancer Management and Research · doi:10.2147/cmar.s210545 · Cited by 73
Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane
Kumar, R., de Mooij, T., Peterson, T. E., Kaptzan, T., Johnson, A. J., Daniels, D. J., & Parney, I. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179012 · Cited by 72
ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma
Iwata, R., Lee, J. H., Hayashi, M., Dianzani, U., Ofune, K., Maruyama, M., Oe, S., Ito, T., Hashiba, T., Yoshimura, K., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz204 · Cited by 72
Guo, X., Qiu, W., Li, B., Qi, Y., Wang, S., Zhao, R., Cheng, B., Han, X., Du, H., Pan, Z., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0430 · Cited by 72
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005147 · Cited by 71
Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action
Take, Y., Koizumi, S., & Nagahisa, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00324 · Cited by 70
Gardell, J. L., Matsumoto, L. R., Chinn, H. K., DeGolier, K., Kreuser, S. A., Prieskorn, B. M., Balcaitis, S. D., Davis, A. D., Ellenbogen, R. G., & Crane, C. A. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001202 · Cited by 70
Drexler, R., Schüller, U., Eckhardt, A., Filipski, K., Hartung, T. I., Harter, P. N., Divé, I., Forster, M.-T., Czabanka, M., Jelgersma, C., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac177 · Cited by 70
Cui, X., Zhao, J., Li, G., Yang, C., Yang, S., Zhan, Q., Zhou, J., Wang, Y., Xiao, M., Hong, B., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12502 · Cited by 70
Kim, G. B., Aragon‐Sanabria, V., Randolph, L. N., Jiang, H., Reynolds, J., Webb, B. S., Madhankumar, A. B., Lian, X. L., Connor, J. R., Yang, J. Y., et al. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.04.011 · Cited by 69
Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis
Sun, T., Xu, Y., Jiang, S., Xu, Z., Cao, B., Sethi, G., Zeng, Y., Kong, Y., & Mao, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00551-x · Cited by 69
Oji, Y., Hashimoto, N., Tsuboi, A., Murakami, Y., Iwai, M., Kagawa, N., Chiba, Y., Izumoto, S., Elisseeva, O. A., Ichinohasama, R., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30182 · Cited by 68
Ma, R., Rei, M., Woodhouse, I. B., Ferris, K., Kirschner, S. A., Chandran, A., Gileadi, U., Chen, J., Pinho, M. P., Ariosa-Morejon, Y., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac107 · Cited by 68
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67
Hu, X., Bardhan, K., Paschall, A. V., Yang, D., Waller, J. L., Park, M. A., Nayak-Kapoor, A., Samuel, T. A., Abrams, S. I., & Liu, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434530 · Cited by 67
Wiese, M., Schill, F., Sturm, D., Pfister, S. M., Hulleman, E., Johnsen, S. A., & Kramm, C. M. (2016) · Klinische Pädiatrie · doi:10.1055/s-0042-105292 · Cited by 67
Akasaki, Y., Kikuchi, T., Homma, S., Koido, S., Ohkusa, T., Tasaki, T., Hayashi, K., Komita, H., Watanabe, N., Suzuki, Y., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1905-7 · Cited by 67
Dong, Z., Liu, Y., Wang, C., Hao, Y., Fan, Q., Yang, Z., Li, Q., Feng, L., & Liu, Z. (2023) · Advanced Materials · doi:10.1002/adma.202308254 · Cited by 67
Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas
Guan, X., Luo, L., Begum, G., Kohanbash, G., Song, Q., Rao, A., Amankulor, N., Sun, B., Sun, D., & Jia, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0923-z · Cited by 66
Beyond glucose: alternative sources of energy in glioblastoma
Caniglia, J. L., Jalasutram, A., Asuthkar, S., Sahagun, J., Park, S. J., Ravindra, A., Tsung, A. J., Guda, M. R., & Velpula, K. K. (2020) · Theranostics · doi:10.7150/thno.53506 · Cited by 66
Proia, T. A., Singh, M., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1066 · Cited by 65
IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis
Lin, W., Niu, R., Park, S., Zou, Y., Kim, S. S., Xia, X., Xing, S., Yang, Q., Sun, X., Yuan, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37306-1 · Cited by 65
Self-citationYuan, W., Zhang, Q., Gu, D., Lu, C., Dixit, D., Gimple, R. C., Gao, Y., Gao, J., Li, D., Shan, D., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3273 · Cited by 65
Self-citationPeptide vaccines for the treatment of glioblastoma
Swartz, A. M., Batich, K. A., Fecci, P. E., & Sampson, J. H. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1676-y · Cited by 64
Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme
Hindy, N. E., Keyvani, K., Pagenstecher, A., Dammann, P. R., Sandalcioglu, I. E., Sure, U., & Zhu, Y. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not071 · Cited by 64
Yu, H., Liu, Y., McFarland, B. C., Deshane, J. S., Hurst, D. R., Ponnazhagan, S., Benveniste, E. N., & Qin, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0004 · Cited by 64
Kessler, A. F., Frömbling, G. E., Gross, F., Hahn, M., Dzokou, W., Ernestus, R.-I., Löhr, M., & Hagemann, C. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0079-9 · Cited by 64
Yi, K., Zhan, Q., Wang, Q., Tan, Y., Fang, C., Wang, Y., Zhou, J., Yang, C., Li, Y., & Kang, C. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa255 · Cited by 64
Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives
Sener, U. T., Ruff, M. W., & Campian, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137046 · Cited by 64
Havaei, S. M., Aucoin, M. G., & Jahanian‐Najafabadi, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.781800 · Cited by 63
Tanzhu, G., Chen, L., Xiao, G., Shi, W., Peng, H., Chen, D., & Zhou, R. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01206-y · Cited by 63
Chonan, M., Saito, R., Shoji, T., Shibahara, I., Kanamori, M., Sonoda, Y., Watanabe, M., Kikuchi, T., Ishii, N., & Tominaga, T. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov090 · Cited by 62
Brown, N. F., McBain, C. A., Nash, S., Hopkins, K., Sanghera, P., Saran, F. H., Phillips, M., Dungey, F. A., Clifton‐Hadley, L., Wanek, K., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156369 · Cited by 62
Cited by
From Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Metadata
- Authors
- Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y.
- Venue
- Journal of Hematology & Oncology
- Published
- 2024-05-08
- Volume
- 17
- Issue
- 1
- Pages
- 31-31
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W4396735748
- Cited by
- 392
- References
- 784
- FWCI
- 91.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.